Robert Barrow, Chief Executive Officer and Director of Definium Therapeutics, Inc. (NASDAQ:DFTX), filed a Form 4 on August 12, 2026, reporting the acquisition of 375,000 common shares through performance share units at a price of $0.00 per share.

Key Highlights

  • Transaction date: August 12, 2026, with 375,000 common shares acquired (transaction code A) at $0.00 per share.
  • Beneficial ownership following transaction: Robert Barrow directly holds 1,473,246 common shares.
  • Source of shares: The shares represent the second tranche of performance share units granted effective March 12, 2025.
  • Vesting condition: Shares remain subject to vesting based on the reporting person's continued employment through March 12, 2028.
  • Performance milestones: Each performance share unit represented a contingent right to receive one common share based on the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
  • Filing type: Filed by one reporting person; signed by Mark Sullivan, Attorney-in-Fact for Robert Barrow.

Robert Barrow's Performance Share Unit Acquisition at Definium Therapeutics

According to the Form 4 filed on August 12, 2026, Robert Barrow, serving as both Chief Executive Officer and Director of Definium Therapeutics, Inc., acquired 375,000 common shares. The filing indicates the transaction code as "A" (acquired), with a stated price of $0.00 per share. Following this transaction, Barrow's direct beneficial ownership stands at 1,473,246 common shares, as reported in the filing.

The filing's footnote explains that the 375,000 common shares represent the second tranche of performance share units granted effective March 12, 2025. According to the filing, these shares "remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028." The filing further states that "each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."

No derivative securities transactions were reported in Table II of the filing. The form was filed by one reporting person and was signed by Mark Sullivan as Attorney-in-Fact for Robert Barrow on August 12, 2026. No amendment date was indicated, confirming this is an original filing.

What Was Disclosed

Definium Therapeutics CEO Robert Barrow reported the acquisition of 375,000 common shares on August 12, 2026, through performance share units tied to clinical and regulatory milestones, bringing his direct beneficial ownership to 1,473,246 common shares.